SVB Leerink starts Kalvista Pharma at OP; PT $31

SVB Leerink initiated coverage of Kalvista Pharmaceuticals (NASDAQ:KALV) with an “outperform” rating and $31 price target. The stock closed at $16.92 on July 26.

Kalvista is creating a new generation of small molecule protease inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME).

“We believe this under-the-radar name, with its two investigational agents, KVD900 and KVD001, targeting plasma kallikrein in different disease settings, could present investors with numerous ways to ‘win’ in the next six-to-12 month,” writes analyst Dae Gon Ha.

He said that while M&A trends in the HAE market suggest that a “de-risked KVD900 could garner interest from large pharma, positive data for VD001 could also lead to non-dilutive financing through Merck.”

Longer term, he said Kalvista’s focus on developing and commercializing small molecule protease inhibitors could open up additional markets beyond HAE and DME.


Sign up to our weekly BioTuesdays newsletter.